Tesamorelin is one of the few peptides in the wider GH/GHRH conversation that carries an actual FDA approval. The Food and Drug Administration cleared it in 2010 under the brand name Egrifta for a narrow purpose: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not approved for general weight loss, bodybuilding, or anti-aging, and the label says so directly. What follows is a report of the published trial evidence, not medical or dosing advice.
What it is
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-44), with a chemical modification that slows its breakdown. It binds GHRH receptors in the pituitary, prompting the gland to release the body's own growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). That IGF-1 rise is both the mechanism and, as you'll see, the thing the label asks clinicians to track. The drug class matters here: this is a secretagogue that nudges endogenous GH, not injected recombinant growth hormone.
The clinical problem it targets is specific. Some people on older antiretroviral regimens developed a redistribution of body fat, with a buildup of visceral adipose tissue (VAT) in the abdomen. VAT is the deep fat around the organs, distinct from the subcutaneous fat under the skin, and it tracks with metabolic problems.
The pivotal trial: NEJM 2007
The first large randomized trial was published in the New England Journal of Medicine by Falutz and colleagues in December 2007. It randomized 412 HIV-infected patients with abdominal fat accumulation (86% male) to a daily subcutaneous injection of 2 mg tesamorelin or placebo for 26 weeks. The primary endpoint was the percent change in VAT, measured by CT scan at the L4-L5 level.
The headline result:
- VAT fell about 15.2% in the tesamorelin group and rose about 5.0% with placebo (p<0.001).
- Triglycerides dropped roughly 50 mg/dL on tesamorelin versus a 9 mg/dL rise on placebo (p<0.001).
- IGF-1 climbed about 81% with tesamorelin while falling around 5% on placebo (p<0.001).
Notably, the study reported no significant differences in glycemic measures between groups over those 26 weeks, which was a relevant question for a GH-axis drug, since growth hormone can worsen glucose handling (Falutz et al., NEJM 2007).
The pooled phase-3 picture
A second confirmatory phase-3 trial followed the same design. Falutz and colleagues later pooled both studies in the Journal of Clinical Endocrinology & Metabolism in 2010. That analysis covered 806 ART-treated patients randomized 2:1 (543 tesamorelin, 263 placebo), again at 2 mg daily, with a 26-week placebo-controlled phase and a 26-week safety extension.
| Endpoint (week 26) | Treatment effect vs placebo |
|---|---|
| Visceral adipose tissue | −15.4% |
| Triglycerides | −12.3% |
| IGF-1 | +108 ± 112 vs −7 ± 64 ng/mL |
| Glucose parameters | No clinically meaningful difference |
VAT reductions seen at 26 weeks were broadly maintained through 52 weeks in patients who stayed on the drug (Falutz et al., JCEM 2010). The effect was selective: subcutaneous fat and overall BMI didn't change much, which is why the label frames this as fat redistribution rather than weight loss.
Approval, and the limits of it
FDA approval came in 2010. The DailyMed label states the indication plainly as "reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy," at a dose of 1.4 mg subcutaneously once daily for the current SV formulation. It also carries an explicit note that the drug is not indicated for weight loss management, consistent with the weight-neutral trial data (EGRIFTA SV label, DailyMed).
A few limits are worth being honest about. The trials enrolled a specific population, HIV patients with lipodystrophy on antiretroviral therapy, and the benefit reverses after stopping: VAT tends to re-accumulate once the drug is withdrawn. The studies measured body composition and lipids, not hard cardiovascular outcomes or mortality.
The IGF-1 caveat
The same mechanism that drives the fat loss is also the safety question. Because tesamorelin pushes GH and raises IGF-1, the label tells prescribers to monitor IGF-1 during therapy and to consider stopping treatment in patients with persistent elevations above roughly 3 standard deviation scores (>3 SDS), particularly when the fat-loss response is weak. The long-term consequences of sustained IGF-1 elevation are described as unknown.
That ties into the contraindications and warnings:
- Contraindicated with active malignancy, disruption of the hypothalamic-pituitary axis, known hypersensitivity, and in pregnancy.
- A warning around neoplasm risk, since IGF-1 is a growth factor; any prior cancer should be inactive.
- Glucose intolerance and new-onset diabetes were reported (about 5% vs 1% with placebo at week 26).
- Fluid retention effects such as edema, arthralgia, and carpal tunnel symptoms.
Injection-site reactions, joint pain, and muscle pain were among the more common adverse events across the program, and overall adverse-event rates were broadly similar to placebo in the controlled phases (LiverTox: Tesamorelin, NIH).
Bottom line for readers
Tesamorelin is a genuinely approved peptide with a documented evidence base: two randomized, placebo-controlled phase-3 trials showing a selective ~15% reduction in visceral fat in HIV-associated lipodystrophy, plus lipid improvements and a neutral effect on glucose over six months. It is also a prescription drug with a defined indication, real contraindications, and a labeled requirement to watch IGF-1. Anything sold outside that approved channel, including research-grade vials marketed for off-label fat loss, sits outside the evidence and the regulatory framework described here. This article reports published findings and is not medical advice.